WTX212A
Phase 1Small molecule
WTX212A is one of 75 small molecule programs targeting Monotherapy. It is currently in Phase 1.
3
Indications
3
Total Trials
3
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
249 competitors in Patients With Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Eloxatin
TevaPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Camptosar
PfizerPhase 2
Tecentriq
RochePhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Trodelvy
GileadPhase 2
Erbitux
IImclone
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Lazcluze
Johnson & JohnsonPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Monotherapy1 trial
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06106152·20 enrolled
Patients With Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for WTX212A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSun Yat-sen University